• Halozyme (HALO) Phase 2 Results of PEGPH20 for Metastatic Pancreatic Cancer

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: Q4 2016
    Designation(s): Fast Track

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Metastatic Pancreatic Cancer
    Lead Indication?: Yes
    Treatment Name: PEGPH20

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Halozyme
    Stock Symbol: HALO
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://www.halozyme.com/investors/news-releases/news-release-details/2016/Halozyme-Reports-Second-Quarter-2016-Financial-Results/default.aspx
    Partnership: Yes

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement



    Presenting key efficacy and safety data from stage 1 of its phase 2 clinical study in metastatic pancreatic cancer patients treated with PEGPH20 at the 2016  American Society of Clinical Oncology  Annual Conference. The results continued to show clinically meaningful efficacy for HA-high patients treated with PEGPH20 plus gemcitabine and ABRAXANE® (nab-paclitaxel) versus gemcitabine and ABRAXANE alone, including median progression free survival of 9.2 months versus 6.0 months. Safety data presented from stage 2 of the study continued to show a reduction in the rate of thromboembolic events in both treatment arms as compared to stage 1.

    The company expects to report mature response rate and progression free survival data from stage 2 of the study in the fourth quarter.



      Report Event

    User Feedback

    There are no reviews to display.